Home » Articles » News

US panel votes to authorize J&J COVID-19 vaccine booster | Inquirer News...

US panel votes to authorize J&J COVID-19 vaccine booster | Inquirer News
"Vials labelled “COVID-19 Coronavirus Vaccine” and syringe are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS FILE PHOTO
WASHINGTON — A high level panel of US medical experts voted unanimously Friday to recommend authorizing a second shot of the Johnson & Johnson Covid vaccine.
The decision will help end a sense of limbo for 15 million Americans who received the first dose but were worried whether it was enough to protect them, particularly after the rise of the Delta variant.
ADVERTISEMENT

The committee members, convened by the Food and Drug Administration (FDA), agreed with the pharmaceutical company that safety and efficacy evidence favored a second dose.
The recommendation may be tweaked further by the FDA and by the Centers for Disease Control and Prevention (CDC), and an emergency use authorization should follow within days to weeks.FEATURED STORIES
NEWSINFO
Roque bares Sara Duterte’s last-minute appeal for him to run for Senate

NEWSINFO
‘Saving’ Manila Bay: Dolomite beach, wetlands drowning in wastes

NEWSINFO
Bongbong, family attend China embassy’s photo wall ribbon-cutting event

Several of the independent experts suggested that though J&J had applied to authorize a booster, a second J&J vaccine should in fact be regarded as an “additional” dose needed to achieve full vaccination.
“I think this frankly was always a two-dose vaccine. It’s hard to recommend this as a one-dose vaccine,” said Paul Offit, a vaccine expert from Children’s Hospital of Philadelphia.

Recommended videosPowered by AnyClip1/7North Korea says US overreacting over missile testRead More



15.5K



5





Video Player is loading.Play VideoUnmuteDuration /Current Time Playback Speed Settings1xLoaded: 0%Remaining Time - FullscreenPlayUp NextThis is a modal window.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window.Playback Speed0.25x0.5x1x Normal1.5x2xReplay the listPowered by AnyClip Privacy Policy

TOP ARTICLES







































North Korea says US overreacting over missile test
NOW PLAYING
UP NEXT





Ethiopia hits Tigray's capital with third airstrike
NOW PLAYING
UP NEXT





Isko Moreno promises to cut tax on fuel, electricity by 50%
NOW PLAYING
UP NEXT





WATCH: OCEAN PARK SA MANILA, BUKAS NA | CHONA YU
NOW PLAYING
UP NEXT





WATCH: MGA MAGSASAKA, UMAARAY NA SA SMUGGLING NG GULAY NA GALING CHINA | CHONA YU
NOW PLAYING
UP NEXT





WATCH: MGA MAGSASAKA, SUMUGOD SA MENDIOLA | CHONA YU
NOW PLAYING
UP NEXT





Atienza: Makabayan endorses Pacquiao
NOW PLAYING
UP NEXT



North Korea says US overreacting over missile test





The panel was also asked to discuss, but not to vote on, the question of so-called “mix and match” boosting, in which a person receives a different brand or type of vaccine as a booster than that used for the initial dose.
But FDA scientist Peter Marks said “it’s possible” that question will be voted on in future.
A preliminary study this week showed that people who have received the J&J vaccine may benefit from a booster dose of a different, messenger-RNA vaccine such as Pfizer or Moderna.
The single shot J&J vaccine was never as effective as its double-shot mRNA counterparts, but some evidence suggests it is less susceptible to waning than Pfizer and Moderna, because of the viral vector technology behind it.
Nevertheless, the company presented data showing efficacy against symptomatic Covid rose from 70 to 94 percent in a US trial after a second dose given two months after the first, similar to figures associated with mRNA vaccines.
ADVERTISEMENT

Friday’s meeting came after the same panel voted Thursday to authorize a booster dose of Moderna’s vaccine for at-risk groups.
In that meeting, the panel decided to authorize a booster dose of Moderna for the over-65s, people aged between 18 and 64 who are at a higher risk of developing a severe version of the coronavirus, and those whose work may involve frequent exposure to the virus.
A similar decision was already reached for the Pfizer vaccine several weeks earlier, with experts concerned a booster might not be suitable for everyone, especially younger males at risk of developing myocarditis (heart inflammation) as a side effect.
But the J&J decision applies more broadly, to everyone over 18 who received the first shot of the vaccine at least two months earlier.
Serious but extremely rare safety concerns include blood clotting with low platelets, particularly in younger women, and Guillain-Barre Syndrome, a rare immune disorder that causes muscle weakness and sometimes temporary paralysis.
.inline_ffff input { width: 70%!important; }
.bypro {
float: right;
width: 71%;
text-align: center;
margin-top: -12px;
margin-right: 15px;
clear: both;
color: #5C5C5C;
font-size: 8px!important;
line-height: 9px!important;

}
.lfform-inquirer-horizontal h2 {
font-weight: bold !important;
font-family: mallory !important;
}
@media only screen and (min-width: 360px) and (max-width: 767px) {
.lfform-inquirer-horizontal #myForm3 {
width: 100%;
display: flex;
flex-wrap: wrap;
justify-content: center;
}
.lfform-inquirer img {
width: 100% !important;
margin: 0 !important;
}
.bypro {
margin-top: 10px;
}
.lfform-inquirer-horizontal input[type=""email""] {

width: 100% !important;
}
.lfform-inquirer-horizontal input[type=""submit""], .lfform-inquirer-horizontal input[type=""button""] {

width: 100% !important;
}
}

.formv4 {
width: 100%!important;
max-width: 100%;
margin: 15px 0;
}
.formv4 input[type=""email""] {
font-weight: bold;
float: left;
-webkit-appearance: none;
margin: 0!important;
width: 70% !important;
}
.formv4 input[type=""submit""] {
font-weight: bold;
width: 28% !important;
padding: 3%;
float: left;
-webkit-appearance: none;
}
.formv4 #myForm3 {
width: 100%;
display: flex;
flex-wrap: wrap;
justify-content: space-between;
}
.formv4 .bypro {
width:100%;
font-family: 'noto serif';
float: unset;
clear: both;
color: #333333;
font-size: 11px!important;

line-height: 1 !important;
margin: 10px 3px;
text-align:left;
}
.formv4 a, .formv4 a:visited, .formv4 a:hover {
color: #0b72b5 !important;
text-decoration: none; !important;
}

.formv4 h2 {
font-weight: bold !important;
text-align: left;
font-family: mallory !important;
color: #333333 !important;
margin:5px 0 !important;
padding: 0 !important;
}
.formv4 p {
width: 100%;
text-align: left;
color: #5A5A5A !important;
font-family: 'noto serif' !important;
font-size: 14px !important;
margin: 0 !important;
line-height: 1.6em !important;
margin-bottom: 15px !important;
padding: 0 !important;
}

@media only screen and (min-width: 360px) and (max-width: 767px) {
.formv4 h2 {

font-size: 16px !important;
}
.formv4 .bypro {
font-size: 12px!important;
margin: 5px 5px;
}
.formv4 input[type=""email""] {

width: 100% !important;
}
.formv4 input[type=""submit""] {
width: 100% !important;
margin: 10px 0;
}
.formv4 {
width: 95%!important;
max-width: 95%;
margin: 20px auto;
}
}

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.

#inqplus-article2 {
width: 100%;
height: 250px;
margin: 20px auto;
background-color: #a5b8c5;
display: flex;
flex-wrap: wrap;
justify-content: space-between;
align-items: flex-start;
}
#inqplus-cta-wrap {
width: 50%;
height: 250px;
background-image: url(/single2017/images/inqplus-sub/inqplus-cta-bg1.png);
background-repeat: no-repeat;
background-size: cover;
}
#inqplus-cta2 {
width: 89%;
height: auto;
margin: 35px auto 0;
}
#inqplus-cta2 img {
width: 100%;
}
#newsletter-cta-wrap {
width: 50%;
height: 250px;
background-image: url(/single2017/images/inqplus-sub/newsletter-bg1.png);
position: relative;
background-repeat: no-repeat;
background-size: cover;
}
#newsletter-cta2 {
width: 95%;
position: absolute;
bottom: -4px;
z-index: 1;
}
#newsletter-cta2 img {
width: 100%;
}
#inqplus-nl-sub2 {
width: 65%!important;
display: flex;
font-size: 0;
box-sizing: border-box;
z-index: 2;
position: absolute;
bottom: 10px;
right: 10px;
}
#inqplus-nl-sub2 form {
width: 100%!important;
}
.sub-input2 {
width: 70%!important;
height: 25px!important;
border: 0!important;
padding: 5px 0 5px 10px!important;
margin: 0!important;
box-sizing: border-box!important;
border-radius:0;
-webkit-appearance:none;
}
.sub-btn2 {
width: 30%!important;
height: 25px!important;
border: 0!important;
padding: 0!important;
margin: 0!important;
background-color: #004a87!important;
color: #f5f5f5!important;
text-transform: uppercase!important;
border-radius:0;
-webkit-appearance:none;
}
/* 414px */
@media only screen and (min-width: 414px) and (max-width: 599px){
#inqplus-article2 {
width: 98%;
height: auto;
}

#inqplus-cta-wrap {
width: 100%;
height: auto;
}

#newsletter-cta-wrap {
width: 100%;
}

#newsletter-cta2 img {
width: 90%;
}

}

/* 320px */
@media only screen and (min-width: 320px) and (max-width: 413px){
#inqplus-article2 {
width: 98%;
height: auto;
}

#inqplus-cta-wrap {
width: 100%;
}

#newsletter-cta-wrap {
width: 100%;
}

}

Read Next

Colmenares welcomes inclusion in Pacquiao, De Guzman’s Senate slate

VerrulonRemove Warts & Skin Tags Safely At Home! Try Out Now!Verrulon|SponsoredSponsoredUndoPerfect-Dating.comAgusan Del Norte is actually full of single handsome guys. Check them out on this free dating sitePerfect-Dating.com|SponsoredSponsoredUndoTips and Tricks[Gallery] Teenage pole vaulter's life is almost ruined after pictures go viralTips and Tricks|SponsoredSponsoredUndoBETER - leading providerSports betting odds, api for sportsbooksBETER - leading provider|SponsoredSponsoredUndoArticles SkillDean Martin's Daughter Finally Confirms the RumorsArticles Skill|SponsoredSponsoredUndoGadgetheoryThe Most Beautiful Women Of All TimeGadgetheory|SponsoredSponsoredUndoTips and TricksA Marine rushes home to greet his wife, but is surprised when he sees her.Tips and Tricks|SponsoredSponsoredUndo

window._taboola = window._taboola || [];
_taboola.push({
mode: 'thumbnails-d',
container: 'taboola-below-article-thumbnails-desktop',
placement: 'Below Article Thumbnails - newsinfo',
target_type: 'mix'
});


window._taboola = window._taboola || [];
_taboola.push({
mode: 'thumbnails-e',
container: 'taboola-below-article-thumbnails-mobile',
placement: 'Below Article Thumbnails - newsinfo',
target_type: 'mix'
});

EDITORS' PICK

Leaked: A 60x Zoom and all-new Helio G96 mean a complete overhaul for TECNO Mobile’s new CAMON 18 series

Delivering delight against all odds

DOJ drug war review: Killer cops had it easy

US FDA clears Moderna, J&J COVID-19 boosters, backs use of different vaccine for boost

Next level mobile photography within reach with vivo X70 co-engineered with ZEISS

Pagasa: Fair weather on Thursday; cooler days coming

MOST READ

Pacquiao bares irregularities in DOE led to higher power costs; Cusi denies claims

Drilon: Tax and then ban Chinese firm in pandemic funds mess

‘Saving’ Manila Bay: Dolomite beach, wetlands drowning in wastes

Robredo to supporters: Be calm, gentle and do good deeds

Don't miss out on the latest news and information.

View comments"
 

Please support us in writing articles like this by sharing this post

Share this post to your Facebook, Twitter, Blog, or any social media site. In this way, we will be motivated to write articles you like.

--- NOTICE ---
If you want to use this article or any of the content of this website, please credit our website (www.affordablecebu.com) and mention the source link (URL) of the content, images, videos or other media of our website.

"US panel votes to authorize J&J COVID-19 vaccine booster | Inquirer News" was written by Mary under the News category. It has been read 61 times and generated 0 comments. The article was created on and updated on 17 November 2021.
Total comments : 0